{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,27]],"date-time":"2026-02-27T04:16:09Z","timestamp":1772165769617,"version":"3.50.1"},"reference-count":10,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T00:00:00Z","timestamp":1574294400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Ophthalmol"],"published-print":{"date-parts":[[2019,12]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Visual impairment occurred as an infrequent form of chemotherapeutic toxicity and was often underestimated despite of several reports. We described a case of acute unilateral visual impairment after one cycle of intravenous chemotherapy of a normal dose, aiming at raising attention to chemotherapy-induced ocular toxicity.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>The patient developed a progressive vision loss in the right eye during the chemotherapy. After one cycle of intravenous chemotherapy, her visual acuity decreased by 0.6 in the right eye (VOD\u2009=\u20090.4) compared to the previous value of 1.0 (VOD\u2009=\u20091.0). No evidence of ocular infiltration was observed from the cerebral magnetic resonance imaging (MRI). During her follow-up period, we documented the ophthalmologic examinations including visual acuity, visual field (VF), visual evoked potential (VEP), electroretinogram (ERG), fundus photograph (FP), fundus fluorescein angiography (FFA) and optical coherence tomography (OCT). Ophthalmoscope examination and fundus photograph showed optic disc edema, fuzzy boundary and linear hemorrhages in her right eye. Fundus fluorescein angiography (FFA) revealed capillary underdevelopment at the nasal and superior temporal area of the optic disc in the early phase and capillary fluorescein leakage in the late phase. The result of VEP test suggested the impaired function of the optic nerve. Thus, a diagnosis of nonarteritic anterior ischemic optic neuropathy (NAION) was made by the ophthalmologist according to these results. The patient was prescribed prednisone combined with neuroprotective drugs, which did not work. After the cessation of chemotherapy, her impaired vision gradually recovered.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>This is the first reported case of acute visual impairment in a patient who underwent chemotherapy of a normal dose. It is indicated that while receiving benefits from chemotherapy, cancer patients simultaneously suffer from the risk of vision loss.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12886-019-1246-3","type":"journal-article","created":{"date-parts":[[2019,11,21]],"date-time":"2019-11-21T09:03:34Z","timestamp":1574327014000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Unilateral visual impairment in a patient undergoing chemotherapy: a case report and clinical findings"],"prefix":"10.1186","volume":"19","author":[{"given":"Xia","family":"Yuan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuliang","family":"Feng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,11,21]]},"reference":[{"issue":"6","key":"1246_CR1","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1023\/B:INTE.0000006763.61637.7e","volume":"24","author":"F Gonzalez","year":"2001","unstructured":"Gonzalez F, Menendez D, Gomez-Ulla F. Monocular visual loss in a patient undergoing cisplatin chemotherapy. Int Ophthalmol. 2001;24(6):301\u20134.","journal-title":"Int Ophthalmol"},{"issue":"7","key":"1246_CR2","first-page":"165","volume":"10","author":"EA Chu","year":"2008","unstructured":"Chu EA, Wu JM, Tunkel DE, Ishman SL. Nasopharyngeal carcinoma: the role of the Epstein-Barr virus. Medscape J Med. 2008;10(7):165.","journal-title":"Medscape J Med"},{"issue":"22","key":"1246_CR3","doi-asserted-by":"publisher","first-page":"4604","DOI":"10.1200\/JCO.2004.10.074","volume":"22","author":"JA Langendijk","year":"2004","unstructured":"Langendijk JA, Leemans CR, Buter J, Berkhof J, Slotman BJ. The additional value of chemotherapy to radiotherapy in locally advanced nasopharyngeal carcinoma: a meta-analysis of the published literature. Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology. 2004;22(22):4604.","journal-title":"Journal of Clinical Oncology Official Journal of the American Society of Clinical Oncology"},{"issue":"1","key":"1246_CR4","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1016\/j.survophthal.2009.06.008","volume":"55","author":"EJ Atkins","year":"2010","unstructured":"Atkins EJ, Bruce BB, Newman NJ, Biousse V. Treatment of Nonarteritic anterior ischemic optic neuropathy. Surv Ophthalmol. 2010;55(1):47\u201363.","journal-title":"Surv Ophthalmol"},{"issue":"11","key":"1246_CR5","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1001\/archopht.1996.01100140566007","volume":"114","author":"N Listed","year":"1996","unstructured":"Listed N. Characteristics of patients with nonarteritic anterior ischemic optic neuropathy eligible for the ischemic optic neuropathy decompression trial. Arch Ophthalmol. 1996;114(11):1366\u201374.","journal-title":"Arch Ophthalmol"},{"issue":"1","key":"1246_CR6","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1016\/S0002-9394(14)70999-7","volume":"123","author":"MG Hattenhauer","year":"1997","unstructured":"Hattenhauer MG, Leavitt JA, Hodge DO, Grill R, Gray DT. Incidence of nonarteritic anterior ischemic optic neuropathy. Am J Ophthalmol. 1997;123(1):103.","journal-title":"Am J Ophthalmol"},{"issue":"2","key":"1246_CR7","doi-asserted-by":"publisher","first-page":"132","DOI":"10.1097\/00041327-200306000-00005","volume":"23","author":"BJ Katz","year":"2003","unstructured":"Katz BJ, Ward JH, Digre KB, Creel DJ, Mamalis N. Persistent severe visual and electroretinographic abnormalities after intravenous Cisplatin therapy. J Neuroophthalmol. 2003;23(2):132\u20135.","journal-title":"J Neuroophthalmol"},{"issue":"3","key":"1246_CR8","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1097\/01.IOP.0000066648.33513.3D","volume":"19","author":"AS Eiseman","year":"2003","unstructured":"Eiseman AS, Flanagan JC, Brooks AB, Mitchell EP, Pemberton CH. Ocular surface, ocular adnexal, and lacrimal complications associated with the use of systemic 5-fluorouracil. Ophthalmic Plast Reconstr Surg. 2003;19(3):216\u201324.","journal-title":"Ophthalmic Plast Reconstr Surg"},{"issue":"2","key":"1246_CR9","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1023\/A:1020613600826","volume":"60","author":"L Delval","year":"2002","unstructured":"Delval L, Klastersky J. Optic neuropathy in cancer patients. Report of a case possibly related to 5 fluorouracil toxicity and review of the literature. J Neurooncol. 2002;60(2):165.","journal-title":"J Neurooncol"},{"issue":"4","key":"1246_CR10","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1097\/00006324-200304000-00004","volume":"80","author":"BA Teitelbaum","year":"2003","unstructured":"Teitelbaum BA, Tresley DJ. Cystic maculopathy with normal capillary permeability secondary to docetaxel. Optometry & Vision Science Official Publication of the American Academy of Optometry. 2003;80(4):277.","journal-title":"Optometry & Vision Science Official Publication of the American Academy of Optometry"}],"container-title":["BMC Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1246-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s12886-019-1246-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s12886-019-1246-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,11,19]],"date-time":"2020-11-19T21:04:19Z","timestamp":1605819859000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcophthalmol.biomedcentral.com\/articles\/10.1186\/s12886-019-1246-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,11,21]]},"references-count":10,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1246"],"URL":"https:\/\/doi.org\/10.1186\/s12886-019-1246-3","relation":{"has-preprint":[{"id-type":"doi","id":"10.21203\/rs.2.9119\/v4","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9119\/v3","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9119\/v2","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.2.9119\/v1","asserted-by":"object"}]},"ISSN":["1471-2415"],"issn-type":[{"value":"1471-2415","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,11,21]]},"assertion":[{"value":"24 February 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 November 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 November 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The report of patient data was approved by the Institutional Animal Care and Use Committee and Ethics Committee.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Written consent was obtained from the patient for the publication of the patient\u2019s details.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors have no conflicts of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"236"}}